Blood, Vol. 113, Issue 18, 4391-4402, April 30, 2009

microRNA expression in the biology, prognosis, and therapy of Waldenström macroglobulinemia
Blood Roccaro et al. 113: 4391

Supplemental materials for: Roccaro et al

Files in this Data Supplement:

• Table S1. Clinical characteristics of WM patients (PDF, 19.5 KB)
  
  
• Table S2. Predicted targets modulated by de-regulated miRNA expression in WM patients (PDF, 18.4 KB)
  
  
• Table S3. Predicted targets modulated after exposure of BCWM1 cells to novel agents active in WM (PDF, 17.8 KB)
  
  
• Figure S1. miRNA-155 (JPG, 89.4 KB) -
  (A) Efficiency of miRNA-155 knockdown probe transfection in WM cells. WM cells (miRNA-155 knockdown probe-, control probe-transfected BCWM.1 cells) were harvested 48 hours after transfection. Not-transfected BCWM.1 cells were used as controls. Detection of miRNA-155 was evaluated by stem-loop qRT-PCR. (B) Efficiency of 5′fluorescein labeled miRNA-155-LNA-knockdown- and control-probe in WM cells. BCWM.1 cells were transfected with either fluorescein-labeled miRNA-155 LNA knockdown probe or fluorescein-labeled control knockdown probe at final concentration of 40nM, using Lipofectamine 2000. Cells were harvested 48h after transfection. Efficiency of transfection has been evaluated using immunofluorescence. (C) Nocodazole does not induce cytotoxicity on either miRNA-155 knockdown probe- or control probe-transfected BCWM.1 cells. Cells were cultured in presence or absence of nocodazole (80 nM) for 24 h, and cytotoxicity were assessed by MTT assay. (D) Efficiency of miRNA-155 knockdown probe transfection in WM cells isolated from mice BM. Detection of miRNA-155 was evaluated from BM of mice injected with either miRNA-155 knockdown probe- or control probe-transfected WM cells, by using stem-loop qRT-PCR for human miRNA-155.